Abstract: Uses of a dual V region antibody-like protein or a fragment of a dual V region antibody-like region.

Abstract: Uses of a dual V region antibody-like protein or a fragment of a dual V region antibody-like region.

Abstract: The present invention provides stable pharmaceutical antibody formulations, including lyophilized formulations, comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffering system, wherein the pH of the formulation is about pH 7, and wherein the formulation has a low salt concentration in order to reduce the ionic strength of the formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing agent. The formulations can be used in the treatment of various diseases.

Abstract: The present invention provides stable pharmaceutical antibody formulations, including lyophilized formulations, comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffering system, wherein the pH of the formulation is about pH 7, and wherein the formulation has a low salt concentration in order to reduce the ionic strength of the formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing agent. The formulations can be used in the treatment of various diseases.

Abstract: Described is a composition comprising:

Abstract: The invention concerns novel cationic polymers of formula (I) in which n is a whole number between 0 and 5 and p is a whole number between 2 and 20,000, more particularly p ranges between 10 and 18,000, and advantageously between 200 and 1,000, characterized in that: at least 10%, advantageously 30 to 80%, preferably 70%, of the free NH2 functions are substituted by identical or different hydrophilic R groups; said cationic polymer can further comprise at least a targeting element associated covalently or not with the free NH2 functions and/or said hydrophilic R groups provided that said cationic: polymer contains at least 20%, preferably at least 30%, of free NH2 functions. The invention also concerns a complex comprising at least said cationic polymer associated with at least a therapeutically active substance, in particular a nucleic acid comprising at least a negative charge. The invention is useful for transferring a nucleic acid into target cells, in particular for gene therapy.

Abstract: The invention concerns novel cationic polymers of formula (I) in which n is a whole number between 0 and 5 and p is a whole number between 2 and 20000, more particularly p ranges between 10 and 18000, and advantageously between 200 and 1000, characterised in that: at least 10%, advantageously 30 to 80%, preferably 70%, of the free NH 2 functions are substituted by identical or different hydrophilic R groups; said cationic polymer can further comprise at least a targeting element associated covalently or not with the free NH 2 functions and/or said hydrophilic R groups provided that said cationic polymer contains at least 20%, preferably at least 30%, of free NH 2 functions. The invention also concerns a complex comprising at least said cationic polymer associated with at least a therapeutically active substance, in particular a nucleic acid comprising at least a negative charge. The invention is useful for transferring a nucleic acid into target cells, in particular for gene therapy.

Abstract: Compositions containing one or more nucleic acids and cationic polymers, and their use in gene therapy, particularly for in vivo nucleic acid transfer.